1. Gliocidin is a nicotinamide-mimetic prodrug that targets glioblastoma.
- Author
-
Chen YJ, Iyer SV, Hsieh DC, Li B, Elias HK, Wang T, Li J, Ganbold M, Lien MC, Peng YC, Xie XP, Jayewickreme CD, van den Brink MRM, Brady SF, Lim SK, and Parada LF
- Subjects
- Animals, Humans, Mice, Cell Line, Tumor, IMP Dehydrogenase metabolism, IMP Dehydrogenase antagonists & inhibitors, IMP Dehydrogenase chemistry, Nicotinamide-Nucleotide Adenylyltransferase metabolism, Nicotinamide-Nucleotide Adenylyltransferase chemistry, Nicotinamide-Nucleotide Adenylyltransferase antagonists & inhibitors, Female, NAD metabolism, Blood-Brain Barrier metabolism, Cryoelectron Microscopy, Niacinamide analogs & derivatives, Niacinamide pharmacology, Niacinamide chemistry, Male, Models, Molecular, Brain Neoplasms drug therapy, Brain Neoplasms pathology, Brain Neoplasms metabolism, Glioblastoma drug therapy, Glioblastoma pathology, Glioblastoma metabolism, Prodrugs pharmacology, Prodrugs chemistry, Prodrugs metabolism, Xenograft Model Antitumor Assays, Temozolomide pharmacology, Temozolomide chemistry
- Abstract
Glioblastoma is incurable and in urgent need of improved therapeutics
1 . Here we identify a small compound, gliocidin, that kills glioblastoma cells while sparing non-tumour replicative cells. Gliocidin activity targets a de novo purine synthesis vulnerability in glioblastoma through indirect inhibition of inosine monophosphate dehydrogenase 2 (IMPDH2). IMPDH2 blockade reduces intracellular guanine nucleotide levels, causing nucleotide imbalance, replication stress and tumour cell death2 . Gliocidin is a prodrug that is anabolized into its tumoricidal metabolite, gliocidin-adenine dinucleotide (GAD), by the enzyme nicotinamide nucleotide adenylyltransferase 1 (NMNAT1) of the NAD+ salvage pathway. The cryo-electron microscopy structure of GAD together with IMPDH2 demonstrates its entry, deformation and blockade of the NAD+ pocket3 . In vivo, gliocidin penetrates the blood-brain barrier and extends the survival of mice with orthotopic glioblastoma. The DNA alkylating agent temozolomide induces Nmnat1 expression, causing synergistic tumour cell killing and additional survival benefit in orthotopic patient-derived xenograft models. This study brings gliocidin to light as a prodrug with the potential to improve the survival of patients with glioblastoma., Competing Interests: Competing interests: The authors declare no competing interests., (© 2024. The Author(s), under exclusive licence to Springer Nature Limited.)- Published
- 2024
- Full Text
- View/download PDF